CA2283193A1 - Proteines secretees et polynucleotides codant ces dernieres - Google Patents

Proteines secretees et polynucleotides codant ces dernieres Download PDF

Info

Publication number
CA2283193A1
CA2283193A1 CA002283193A CA2283193A CA2283193A1 CA 2283193 A1 CA2283193 A1 CA 2283193A1 CA 002283193 A CA002283193 A CA 002283193A CA 2283193 A CA2283193 A CA 2283193A CA 2283193 A1 CA2283193 A1 CA 2283193A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
polynucleotide
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002283193A
Other languages
English (en)
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Racie
David Merberg
Maurice Treacy
Vikki Spaulding
Michael J. Agostino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2283193A1 publication Critical patent/CA2283193A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux polynucléotides et les protéines codées par ces derniers.
CA002283193A 1997-03-11 1998-03-09 Proteines secretees et polynucleotides codant ces dernieres Abandoned CA2283193A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81538197A 1997-03-11 1997-03-11
US3632198A 1998-03-06 1998-03-06
US08/815,381 1998-03-06
US09/036,321 1998-03-06
PCT/US1998/004601 WO1998040404A2 (fr) 1997-03-11 1998-03-09 Proteines secretees et polynucleotides codant ces dernieres

Publications (1)

Publication Number Publication Date
CA2283193A1 true CA2283193A1 (fr) 1998-09-17

Family

ID=26713058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283193A Abandoned CA2283193A1 (fr) 1997-03-11 1998-03-09 Proteines secretees et polynucleotides codant ces dernieres

Country Status (5)

Country Link
EP (1) EP0970109A2 (fr)
JP (1) JP2001514520A (fr)
AU (1) AU6546898A (fr)
CA (1) CA2283193A1 (fr)
WO (1) WO1998040404A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144603A3 (fr) * 1999-01-22 2002-02-06 Memorec Medical Molecular Research Cologne Stoffel GmbH Protease
US7060281B1 (en) 1999-06-18 2006-06-13 Research Foundation Of The State University Of New York Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
US6833240B2 (en) 2000-03-08 2004-12-21 Mcgill University Very low density lipoprotein receptor polymorphisms and uses therefor
US20020132244A1 (en) 2000-09-27 2002-09-19 Xiao-Cheng Li-Sucholeiki Methods for detecting rare polymorphic variants in genomic DNA sequences
WO2012068463A2 (fr) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Méthodes de traitement de l'obésité par inhibition de la nicotinamide n-méthyltransférase (nnmt)
AU2019364829A1 (en) * 2018-10-25 2021-06-03 Ajinomoto Co., Inc. Method for secretory production of protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby

Also Published As

Publication number Publication date
WO1998040404A2 (fr) 1998-09-17
AU6546898A (en) 1998-09-29
EP0970109A2 (fr) 2000-01-12
JP2001514520A (ja) 2001-09-11
WO1998040404A3 (fr) 1998-12-30

Similar Documents

Publication Publication Date Title
CA2269755A1 (fr) Proteines secretees et polynucleotides codant ces proteines
CA2278595A1 (fr) Proteines secretees et polynucleotides codant celles-ci
CA2285554A1 (fr) Proteines secretees et polynucleotides les codant
CA2283631A1 (fr) Proteines secretees et polynucleotides les codant
CA2288343A1 (fr) Proteines secretees et polynucleotides les codant
CA2283195A1 (fr) Proteines secretees et polynucleotides les codant
CA2274732A1 (fr) Proteines secretees et polynucleotides codant pour lesdites proteines
CA2306457A1 (fr) Proteines secretees et polynucleotides les codant
CA2286290A1 (fr) Proteines secretees et polynucleotides codant ces proteines
EP1032593A1 (fr) Proteines secretees et polynucleotides les codant
CA2281059A1 (fr) Proteines secretees et polynucleotides les codant
CA2278770A1 (fr) Proteines secretees et polynucleotides les codant
CA2283193A1 (fr) Proteines secretees et polynucleotides codant ces dernieres
CA2276088A1 (fr) Proteines secretees et polynucleotides les codant
CA2293363A1 (fr) Proteines secretees et polynucleotides les codant
CA2284109A1 (fr) Proteines secretees et polynucleotides les codant
CA2273845A1 (fr) Proteines secretees et polynucleotides les codant
CA2278153A1 (fr) Proteines secretees et polynucleotides codant ces proteines
CA2276085A1 (fr) Proteines secretees et polynucleotides les codant
CA2281015A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
CA2278104A1 (fr) Proteines secretees et polynucleotides les codant
WO1998001553A2 (fr) Proteines secretees et polynucleotides codant lesdites proteines
EP0895539A2 (fr) Proteines secretees et polynucleotides les codant
CA2291485A1 (fr) Proteines secretees et polynucleotides codant ces proteines
CA2280968A1 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
FZDE Dead